Biologics demand is carrying the hard parts
- Stevanato sells glass drug containers, injectable drug delivery systems, and the equipment used to make them.
- High-value solutions, meaning premium syringes, cartridges, and ready-to-use products, were 47% of revenue in Q1 2026.
- GLP-1 drugs were about 21% to 22% of total revenue in Q1 2026, giving the company a direct link to a fast drug category.
- The BDS segment grew 13% on a reported basis in Q1 2026, while Engineering revenue fell 31%.
- The Fishers, Indiana plant could help localize U.S. supply, but it still needs volume to stop hurting margins.
- Finn's view is balanced because growth is real, but the price and execution risks leave less room for mistakes.
A GLP-1 supplier with margin work to do
The bull case is simple. Stevanato sells the picks and tools that drug companies need for biologic medicines, including GLP-1 drugs, monoclonal antibodies, and other injected treatments. These drugs often need better containers and better delivery systems than older medicines. That moves customers toward high-value solutions, the company's premium syringes, cartridges, and ready-to-use products.
That shift is already visible. High-value solutions were 49% of total revenue in Q3 2025 and 47% in Q1 2026. GLP-1 drugs were about 21% to 22% of total revenue in Q1 2026. Management is also converting an underused ready-to-use vial line in Piombino Dese into a ready-to-use cartridge line, which shows demand has moved faster than expected.
The bear case is also clear. New plants in Fishers and Latina add cost before they are fully loaded with orders. Engineering, the segment that sells glass conversion, inspection, assembly, and packaging equipment, is still weak. In Q1 2026 its revenue fell 31%, mainly because backlog was low and new orders were slow.
For the next year, the story depends on three watch points: Fishers adding commercial volume, Engineering turning quotes into signed orders, and vial demand continuing to recover after customer destocking. The setup is attractive, but the stock needs proof that growth can turn into better earnings.
Paid when drug makers scale injections
Stevanato makes money by selling primary packaging, delivery systems, contract manufacturing, and equipment to pharma, biotech, and life sciences customers. Primary packaging means the container that directly touches the medicine, such as a vial, syringe, or cartridge.
The best economics come when customers buy high-value solutions. These include ready-to-use vials, high-value syringes, EZ-fill cartridges, and products made for sensitive biologic drugs. Customers pay more because these products can reduce contamination risk, support automated filling, and work better with injection devices.
The company is trying to become an end-to-end partner. A drug company might buy glass containers, use Stevanato device manufacturing, and also buy equipment for its own factory. This can make customer ties stronger, but it also means Stevanato must execute large projects across several plants.
Where the model breaks is utilization. A new plant has people, equipment, depreciation, and quality work before it reaches full output. Fishers and Latina are strategically useful, especially for U.S. supply, but they can weigh on margins until volume catches up.
Containers, devices, and the machines behind them
High-value syringes
These are premium pre-fillable syringes used for more sensitive drugs. Q1 2026 growth was led by syringes, which rose more than 20% year over year.
EZ-fill cartridges
Cartridges are used in pen injectors and similar devices. Stevanato's EZ-fill cartridges were selected for a GLP-1 biosimilar in 2025, and management is adding more cartridge capacity.
Vials
Vials are a core drug container product. Demand was hurt by industry destocking in 2024, but management said in Q1 2025 that order intake was growing double digits for both bulk and ready-to-fill vials.
Pen and auto-injector systems
These products help patients take injected drugs at home. They connect Stevanato to the shift from hospital injections to self-administered medicines.
Contract manufacturing for devices
Stevanato can manufacture device components or assemblies for drug companies. The Fishers site is being built out for device programs, with commercial production expected at the end of 2026 or early 2027.
Engineering equipment
This segment sells equipment for glass conversion, inspection, assembly, and packaging. It has been a drag because customers are taking longer to approve capital projects.
Alba portfolio
Alba is a next-generation product family aimed at highly sensitive drug products. It supports the same biologics trend that is lifting premium syringes and cartridges.
BDS now carries most of the company
The segment mix uses Q1 2026 revenue: EUR 249 million from BDS out of EUR 273.6 million total revenue, with the rest from Engineering. This makes the company heavily tied to BDS demand and to the ramp of high-value drug containment products.
What could break the setup
Fishers and Latina stay underused
High impact · Medium oddsStevanato is spending heavily to add capacity in Fishers, Indiana and Latina, Italy. New plants can hurt margins until they run at higher volume. Q1 2026 margin improvement helped the case, but higher depreciation still offset part of the benefit.
Engineering orders do not return
Medium impact · High oddsEngineering revenue fell 19% in Q3 2025 and 31% in Q1 2026. Management says the pipeline exists, but customers are taking longer to make capital spending decisions. If backlog does not rebuild, the segment can keep dragging revenue and profit.
GLP-1 exposure turns from help to concentration
High impact · Medium oddsGLP-1 drugs were about 21% to 22% of total revenue in Q1 2026. That is a strong tailwind while demand rises, but it also makes Stevanato more exposed to delays, price pressure, or changes in customer launch plans in one major drug category.
Tariffs and currency keep hitting profit
Medium impact · Medium oddsManagement's 2025 guidance assumed a 10% tariff rate for goods shipped from the EU to the U.S., with about EUR 4.5 million of operating profit impact. Foreign exchange also became a larger headwind in 2025, with expected full-year pressure of $15 million to $16 million.
Vial recovery stalls
Medium impact · Medium oddsVials were hurt by industry destocking in 2024, when customers worked down excess inventory. Management later said order intake was improving, but the recovery still needs to show up in steady shipments. A weak vial rebound would reduce one support for BDS growth.
In one breath
What does Stevanato Group do?
Stevanato makes glass containers, injection devices, and production equipment for drug companies. Its products are used for medicines such as biologics, GLP-1 drugs, and other injectable treatments.
Why do GLP-1 drugs matter for STVN?
GLP-1 drugs often need syringes, cartridges, pens, and other delivery parts. In Q1 2026, GLP-1 drugs were about 21% to 22% of Stevanato's total revenue, so demand in that category is a major growth driver.
What is the main risk for Stevanato stock?
The biggest risk is execution. Stevanato needs its new capacity in Fishers and Latina to fill up, while also fixing the slow Engineering segment.
Is Stevanato only a GLP-1 company?
No. GLP-1 drugs are important, but Stevanato also serves monoclonal antibodies, other biologics, diagnostics, and broader injectable drug markets. The key question is whether growth stays broad enough outside GLP-1.